25 citations
,
March 2017 in “International Journal of Dermatology” Ruxolitinib effectively and safely regrows hair in alopecia patients.
22 citations
,
September 2017 in “Skin appendage disorders” Ruxolitinib helped a man regrow his beard after years of hair loss.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
December 2025 in “PubMed” Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
3 citations
,
March 2021 in “Clinical, Cosmetic and Investigational Dermatology” Early treatment of Lupus Erythematosus Alopecia can prevent permanent hair loss, and various medications are effective.
3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
June 2019 in “Poster presentations” Most patients with rheumatoid arthritis continued methotrexate treatment over two years, but those who stopped and restarted experienced more side effects and less improvement.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
June 2019 in “Poster presentations” Low dose methotrexate does not increase hair fall and may reduce it.
June 2016 in “Annals of the rheumatic diseases” Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.
18 citations
,
January 2017 in “Journal der Deutschen Dermatologischen Gesellschaft” High and low doses of prednisolone helped 62% of children with severe alopecia regrow hair with some weight gain and mild acne as side effects.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
6 citations
,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
3 citations
,
June 2023 in “Journal of dermatological treatment” Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.
June 2013 in “Annals of the rheumatic diseases” Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
April 2023 in “Journal of Investigative Dermatology” Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
June 2025 in “Veterinary Sciences” Oclacitinib effectively treated a diabetic cat's severe skin issues without raising glucose levels, and surgery fixed eyelid fusion.
February 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair and improve psoriasis.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.